Literature DB >> 1316933

Interallelic V(D)J trans-rearrangement within the beta T cell receptor gene is infrequent and occurs preferentially during attempted D beta to J beta joining.

J C Aster1, J Sklar.   

Abstract

Previous work has demonstrated that intergenic V(D)J rearrangement, a process referred to as trans-rearrangement, occurs at an unexpectedly high frequency. These rearrangements generate novel V(D)J combinations which could conceivably have some role in the normal immune system, and since they probably arise through chromosomal rearrangements akin to those associated with lymphoid neoplasia, they may also serve as a model for investigating recombinational events which underlie oncogenesis. In view of the existence of a mechanism that permits relatively frequent intergenic trans-rearrangements, it seems reasonable that interallelic trans-rearrangements involving segments belonging to each of the two alleles of a single antigen receptor gene might also occur. To determine the frequency of such rearrangements, we examined thymocytes of F1 progeny of a cross between SWR mice, which have a deletion spanning 10 of the known V beta segments, and NZW mice, which have a deletion involving all J beta 2 segments. Rearranged TCR-beta genes containing V beta segments from the NZW chromosome and J beta segments from the SWR chromosome were amplified from the DNA of F1 thymocytes with the polymerase chain reaction. Using this approach, we found that such rearrangements are relatively uncommon, being present in about 1 in 10(5) thymocytes, a frequency lower than that of V gamma/J beta intergenic trans-rearrangements. The ratio of conventional cis-rearrangement to interallelic trans-rearrangement for any particular V beta segment appears to be about 10(4):1. The structure of the junctions in all trans-rearrangements analyzed closely resembles conventional cis-rearrangements, indicating involvement of V(D)J recombinase in the ultimate joining event. However, in contrast to cis-rearrangements, a strong bias for inclusion of D beta 1 segments over D beta 2 segments was noted, suggesting that interallelic trans-rearrangement may occur preferentially during attempted D-J joining. J beta 2 segment usage in trans-rearrangements also appeared to differ from that expected from previously studied cis-rearrangements. The results have implications with respect to the events and timing of conventional cis-rearrangement during thymocyte differentiation, and the prevalence of various types of trans-rearrangements.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316933      PMCID: PMC2119263          DOI: 10.1084/jem.175.6.1773

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

Review 1.  A view of interphase chromosomes.

Authors:  L Manuelidis
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

2.  Somatic diversification of the chicken immunoglobulin light chain gene is limited to the rearranged variable gene segment.

Authors:  C B Thompson; P E Neiman
Journal:  Cell       Date:  1987-02-13       Impact factor: 41.582

3.  Immunoglobulin double-isotype expression by trans-mRNA in a human immunoglobulin transgenic mouse.

Authors:  A Shimizu; M C Nussenzweig; T R Mizuta; P Leder; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

4.  Determination of nucleotide sequences in DNA.

Authors:  F Sanger
Journal:  Science       Date:  1981-12-11       Impact factor: 47.728

Review 5.  The human T cell receptor genes are targets for chromosomal abnormalities in T cell tumors.

Authors:  T Boehm; T H Rabbitts
Journal:  FASEB J       Date:  1989-10       Impact factor: 5.191

6.  Somatic diversification of immunoglobulin heavy chain VDJ genes: evidence for somatic gene conversion in rabbits.

Authors:  R S Becker; K L Knight
Journal:  Cell       Date:  1990-11-30       Impact factor: 41.582

7.  Hybrid T cell receptor genes formed by interlocus recombination in normal and ataxia-telangiectasis lymphocytes.

Authors:  S Lipkowitz; M H Stern; I R Kirsch
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

8.  The V beta 17+ T cell repertoire: skewed J beta usage after thymic selection; dissimilar CDR3s in CD4+ versus CD8+ cells.

Authors:  S Candéias; C Waltzinger; C Benoist; D Mathis
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

9.  Consistent breakage between consensus recombinase heptamers of chromosome 9 DNA in a recurrent chromosomal translocation of human T cell leukemia.

Authors:  B Tycko; T C Reynolds; S D Smith; J Sklar
Journal:  J Exp Med       Date:  1989-02-01       Impact factor: 14.307

10.  Relative V beta transcript levels in thymus and peripheral lymphoid tissues from various mouse strains. Inverse correlation of I-E and Mls expression with relative abundance of several V beta transcripts in peripheral lymphoid tissues.

Authors:  C Y Okada; I L Weissman
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

View more
  5 in total

1.  Assessing the pathogenic potential of the V(D)J recombinase by interlocus immunoglobulin light-chain gene rearrangement.

Authors:  S N Bailey; N Rosenberg
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

2.  Non-standard D region usage by human TCRB sequences.

Authors:  S J Bowman; J S Lanchbury
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

3.  Cryptic signals and the fidelity of V(D)J joining.

Authors:  S M Lewis; E Agard; S Suh; L Czyzyk
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

4.  Different TCRBV genes generate biased patterns of V-D-J diversity in human T cells.

Authors:  E Quiròs Roldan; A Sottini; A Bettinardi; A Albertini; L Imberti; D Primi
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

5.  Restrictions limiting the generation of DNA double strand breaks during chromosomal V(D)J recombination.

Authors:  Robert E Tillman; Andrea L Wooley; Maureen M Hughes; Tara D Wehrly; Wojciech Swat; Barry P Sleckman
Journal:  J Exp Med       Date:  2002-02-04       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.